Antonio Beltran, MD
Urology · Lincoln, NENPI 1811940596
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (39.8%), consulting fees and education — rather than concentrated in one kind of arrangement. Uromedica, Incorporated accounts for 82.5% of it on its own, with 18 other manufacturers making up the rest. Among urology clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 59 payments — averaging $872.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Uromedica, Incorporated$42K
- Intuitive Surgical$8K
- Axonics, Inc.$239
- Teleflex LLC$180
- Neotract Inc.$145
- Inari Medical, Inc.$142
- plus $556 from 13 others
What the payments were for
- Consulting fees$17,00033%
- Speaking & faculty fees$20,50040%
- Travel & lodging$5,15910%
- Food & beverage$1,1892%
- Education$7,62915%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Uromedica, Incorporated | 23 | $42,467 |
| Intuitive Surgical | 6 | $7,749 |
| Axonics, Inc. | 3 | $239 |
| Teleflex LLC | 3 | $180 |
| Neotract Inc. | 2 | $145 |
| Inari Medical, Inc. | 1 | $142 |
| Boston Scientific | 7 | $138 |
| Johnson & Johnson | 1 | $94 |
| Procept Biorobotics Corporation | 1 | $62 |
| AstraZeneca | 2 | $49 |
| Coloplast | 2 | $36 |
| Agiliti Surgical, Inc. | 1 | $33 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $25 |
| GSK | 1 | $24 |
| Cook Medical LLC | 1 | $22 |
| Olympus America Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| AbbVie | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ProACT$42,443
- Da Vinci Surgical System$7,710
- Axonics r-SNM System$223
- UroLift$148
- FlowTriever$142
- ClotTriever$142
- Bulkamid$106
How this compares
$51,477 in reported general payments places this provider in the 90th percentile of 79 urology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 77 | $56,235 |
| Trimethoprim | 58 | $2,996 |
| Tamsulosin Hcl | 249 | $2,816 |
| NitrofurantoinNitrofurantoin Macrocrystal | 52 | $2,172 |
| Oxybutynin Chloride ErOxybutynin Chloride | 104 | $1,820 |
| Finasteride | 103 | $1,650 |
| Estradiol | 15 | $1,069 |
| Ciprofloxacin Hcl | 117 | $965 |
| Dutasteride | 15 | $877 |
| Testosterone Cypionate | 11 | $624 |
| Doxazosin Mesylate | 37 | $602 |
| Solifenacin Succinate | 16 | $500 |
| Amitriptyline Hcl | 68 | $493 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 31 | $395 |
| Cephalexin | 70 | $378 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $18 | $56,23577 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 79 urology providers in Nebraska.
Other urology in Lincoln
- Thomas BrushLincoln$15K
- Adam MuesLincoln$14K
- Lance WiebuschLincoln$13K
- David WiltfongLincoln$13K
- Logan McGuffeyLincoln$10K
- Aaron PomajzlLincoln$9K
- Tara KirkpatrickLincoln$8K
- Brandon HensleeLincoln$7K
- Andrew LepinskiLincoln$4K
- Jonathan HenningLincoln$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.